Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases
Obinutuzumab (G) has become part of front-line treatment of follicular lymphoma (FL) based on results of a large randomized study. Data on patients treated outside of clinical trials are lacking. We have retrospectively investigated efficacy and safety of G-based immunochemotherapy regimens in 114 p...
Main Authors: | Davor Galusic, Sandra Basic-Kinda, Andela Pijuk, Vibor Milunovic, Barbara Dreta, Neven Franjic, Bozena Coha, Jasminka Sincic-Petricevic, Petar Gacina, Vlatko Pejsa, Marko Lucijanic, Igor Aurer |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-12-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000807 |
Similar Items
-
P1110: EFFICACY AND SAFETY OF IMMUNOCHEMOTHERAPY IN TREATMENT OF FOLLICULAR NON-HODGKIN’S LYMPHOMA DURING COVID-19 PANDEMIC: A STUDY OF KROHEM, THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES
by: D. Galusic, et al.
Published: (2022-06-01) -
Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
by: Branimir Jakšić, et al.
Published: (2018-01-01) -
P1568: EARLY, BUT NOT LATE USE OF REMDESVIR AND CONVALESCENT PLASMA REDUCES MORTALITY OF COVID 19 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES – A STUDY OF KROHEM
by: I. Aurer, et al.
Published: (2022-06-01) -
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
by: Igor Aurer, et al.
Published: (2024-01-01) -
PB2018: MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM RELAPSE IN THE ERA OF NOVEL DRUGS - A MULTICENTER RETROSPECTIVE STUDY FROM THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGICAL MALIGNANCIES (KROHEM)
by: Z. Mitrovic, et al.
Published: (2022-06-01)